Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA.
Ontology highlight
ABSTRACT: Mucopolysaccharidosis type IVA (MPS IVA) is a lysosomal storage disease caused by mutations in the N-acetylgalactosamine-6-sulfatase (GALNS) gene. Skeletal dysplasia and the related clinical features of MPS IVA are caused by disruption of the cartilage and its extracellular matrix, leading to a growth imbalance. Enzyme replacement therapy (ERT) with recombinant human GALNS has yielded positive results in activity of daily living and endurance tests. However, no data have demonstrated improvements in bone lesions and bone grow thin MPS IVA after ERT, and there is no correlation between therapeutic efficacy and urine levels of keratan sulfate, which accumulates in MPS IVA patients. Using qualitative and quantitative proteomics approaches, we analyzed leukocyte samples from heal
SUBMITTER: Alvarez VJ
PROVIDER: S-EPMC7795692 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA